



ASX release

20 December 2017

## **Appointment of Niall Cairns as non-executive director**

AtCor Medical Holdings Limited (ASX: ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, today announced the appointment of Niall Cairns as a non-executive director with effect from today, 20 December 2017.

Mr Cairns is a Sydney based technology growth investor with a 25-year track record of value creation, restructuring, and exits in both listed and unlisted companies having assisted in driving the global growth of over 50 companies in sectors as diverse as digital media, Agtech, Medtech, consumer Internet, and SaaS based businesses. Niall is currently the Chairman of ComOps Limited and a non-executive director of Chant West Holdings and Tru-Test Limited.

Niall Cairns said: "Having known AtCor for many years, I am looking forward to working with the Board and the CEO, to help develop and execute on the new vision and strategy for the Company".

Donal O'Dwyer, AtCor's Chairman, said: "Niall has a successful record as an investor and developer of technology growth companies globally. Importantly, Niall has known the Company and management for a number of years and has recently returned as a shareholder. Based in Sydney, Niall brings a new range of expertise and contacts to the business, which will assist us greatly as we develop and execute on our strategic plan through 2018 and beyond".

Craig Cooper, AtCor's CEO, said: "As we put in place the building blocks for growth it's important to have Board members that can help with our strategic objectives and add value to the Company. Niall has a long-term track record in building shareholder value and I look forward to working closely with him and our other Board members in order to execute on our growth plan."

Commensurate with Niall's appointment the Company also announced the retirement of Duncan Ross from the Board of Directors. The Board would like to thank Duncan for his strategic advice, counsel, and executive governance of the Company during his tenure as a Director.

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact  
(AtCor):*

Donal O'Dwyer – Chairman  
+61 (2) 9874 8761

Peter Manley –CFO  
+61 (2) 8815 8811

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)